Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q3 FY262026-06-30 | Q2 FY262026-03-31 | Q1 FY262025-12-31 | Q4 FY252025-09-30 | Q3 FY252025-06-30 | Q2 FY252025-03-31 | Q1 FY252024-12-31 | Q4 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $118.38M | $110.72M | $103.70M | $99.01M | $96.06M | $92.79M | $88.71M | $84.71M |
| Cost of revenue | $55.92M | $53.59M | $49.73M | $48.17M | $44.76M | $46.77M | $45.87M | $46.48M |
| Gross profit | $62.45M | $57.12M | $53.97M | $50.84M | $51.30M | $46.03M | $42.84M | $38.23M |
| Gross margin | 52.8% | 51.6% | 52.0% | 51.3% | 53.4% | 49.6% | 48.3% | 45.1% |
| Research and development | $18.03M | $19.70M | $17.13M | $17.01M | $18.05M | $23.92M | $21.31M | $21.13M |
| Selling, general and administrative | $80.71M | $76.09M | $69.74M | $63.76M | $63.37M | $63.67M | $56.18M | $53.14M |
| Operating expenses | $98.73M | $102.99M | $86.87M | $80.77M | $81.42M | $87.59M | $77.48M | $74.28M |
| Operating income | −$36.28M | −$45.86M | −$32.90M | −$29.93M | −$30.12M | −$41.56M | −$34.64M | −$36.04M |
| Operating margin | -30.6% | -41.4% | -31.7% | -30.2% | -31.4% | -44.8% | -39.1% | -42.5% |
| EBITDA | −$29.50M | −$32.24M | −$26.71M | −$23.93M | −$24.06M | −$35.16M | −$28.26M | −$74.32M |
| Interest income | $1.50M | $1.71M | $2.18M | $2.63M | $2.69M | $2.80M | $3.24M | $3.62M |
| Income before taxes | −$34.74M | −$43.98M | −$30.25M | −$26.88M | $20.58M | −$39.15M | −$31.50M | −$34.75M |
| Income taxes | $311.00K | $43.00K | $253.00K | $257.00K | $191.00K | $175.00K | $97.00K | −$96.00K |
| Net income | −$35.05M | −$44.02M | −$30.51M | −$27.14M | $20.39M | −$39.33M | −$31.59M | −$34.66M |
| Net margin | -29.6% | -39.8% | -29.4% | -27.4% | 21.2% | -42.4% | -35.6% | -40.9% |
| EPS, basic | −$0.56 | −$0.71 | −$0.50 | −$0.45 | $0.34 | −$0.66 | −$0.53 | −$0.59 |
| EPS, diluted | −$0.56 | −$0.71 | −$0.50 | −$0.45 | $0.33 | −$0.66 | −$0.53 | −$0.59 |
| Diluted shares | 62.40M | 61.70M | 61.08M | 59.81M | 61.16M | 59.65M | 59.16M | 58.02M |
Figures describe Twist Bioscience shares, not any token. As of Aug 3, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.